

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Inpatient Hospitalization and Mortality Rate Trends from 2004 – 2014 in the United States: A Propensity Score-Matched Case-Control Study of Hyperkalemia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059324
Article Type:	Original research
Date Submitted by the Author:	15-Nov-2021
Complete List of Authors:	Tecson, Kristen; Baylor Scott & White Research Institute, Baylor Heart and Vascular Institute; Texas A&M University College of Medicine, Health Science Center Baker, Rebecca; Baylor Scott & White Research Institute, Baylor Heart and Vascular Institute Clariday, Laura; Baylor Scott & White Research Institute, Baylor Heart and Vascular Institute McCullough, Peter; Cardiorenal Society of America
Keywords:	Heart failure < CARDIOLOGY, Other metabolic, e.g. iron, porphyria < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Acute renal failure < NEPHROLOGY, Chronic renal failure < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Inpatient Hospitalization and Mortality Rate Trends from 2004 – 2014 in the United**
4
5 **States: A Propensity Score-Matched Case-Control Study of Hyperkalemia**
6
7

8 Kristen M. Tecson, PhD^{1,2,3}; Rebecca A. Baker, MSN, APRN, ACNS-BC^{1,2}; Laura Clariday,
9
10
11 CCRC^{1,2}; Peter A. McCullough, MD, MPH⁴
12
13

- 14 1. Baylor Heart and Vascular Institute, Dallas, TX
 - 15 2. Baylor Scott & White Research Institute, Dallas, TX
 - 16 3. Texas A&M University College of Medicine, Dallas, TX
 - 17 4. Cardiorenal Society of America, Phoenix, AZ
- 18
19
20
21

22 **Correspondence:**

23 Kristen M. Tecson, PhD
24 621 N Hall Street, Suite H-030
25 Dallas, TX 75226
26 Kristen.Tecson@bswhealth.org
27 214.820.5451
28
29
30
31

32 **Word Count:** 3611
33

34
35 **Keywords:** Hyperkalemia, potassium, National Inpatient Sample, hospitalization, mortality,
36
37 heart failure, kidney disease, diabetes mellitus
38
39

40 **Funding:** This work was supported by a grant ('ESR-19-20263') from AstraZeneca to the
41
42 Baylor Scott & White Research Institute.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To study the trends of hyperkalemia in United States inpatient hospitalization records with heart failure (HF), chronic kidney disease (CKD), acute kidney injury (AKI), and/or type II diabetes mellitus (T2DM) from 2004-2014 with respect to prevalence and inpatient mortality

Design: Observational cross-sectional and propensity score-matched case-control study

Setting: The National Inpatient Sample (representing up to 97% of inpatient hospital discharge records in the United States) from 2004-2014

Participants: 120,513,483(\pm 2,312,391) adult inpatient hospitalization records with HF, CKD/ESRD, AKI, and/or T2DM

Exposure: Hyperkalemia, defined as the presence of an ICD-9-CM code of '276.7' in any of the first 15 diagnostic codes

Primary and Secondary Outcome Measures: The outcomes of interest are the annual rates of hyperkalemia prevalence and inpatient mortality.

Results: Among 120,513,483(\pm 2,312,391) adult inpatient hospitalizations with HF, CKD/ESRD, AKI, and/or T2DM, we found a 28.9% relative increase of hyperkalemia prevalence from 4.94% in 2004 to 6.37% in 2014 ($p<0.001$). Hyperkalemia was associated with an average of 4 percentage points higher rate of inpatient mortality (1.71 post-matching, $p<0.0001$). Inpatient mortality rates decreased from 11.49% \pm 0.17% to 6.43% \pm 0.08% and 9.67% \pm 0.13% to 5.05% \pm 0.07% for matched cases with and without hyperkalemia, respectively ($p<0.001$).

1
2
3 **Conclusions:** Hyperkalemia prevalence increased over time and was associated with greater
4 inpatient mortality, even after accounting for presentation characteristics. We detected a
5 decreasing trend in inpatient mortality risk, regardless of hyperkalemia presence.
6
7
8
9

10 **Keywords:** Hyperkalemia, potassium, National Inpatient Sample, hospitalization, mortality,
11 heart failure, kidney disease, diabetes mellitus
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Article Summary

In this study of 120,513,483 ($\pm 2,312,391$) adult inpatient hospitalization records with heart failure, chronic kidney disease, end stage renal disease, acute kidney injury, and/or type II diabetes mellitus, we found a relative increase of 28.9% in hyperkalemia prevalence (from 4.94% in 2004 to 6.37% in 2014). We found that hospitalizations in which hyperkalemia occurred were far more likely to be severe in nature and that the presence of hyperkalemia was associated with a higher rate of inpatient mortality. After controlling for primary diagnosis, severity of illness, comorbidities, hospital characteristics, and socio-demographics via propensity score matching, we found that the presence of hyperkalemia was still associated with a higher mortality rate (average absolute difference=1.71%, average relative difference=25.3%, $p < 0.0001$), and the rate decreased similarly between groups over time, decreasing from 11.49% \pm 0.17% to 6.43% \pm 0.08% for cases with hyperkalemia and from 9.67% \pm 0.13% to 5.05% \pm 0.07% for cases without hyperkalemia.

Strengths and Limitations

- This is a large study, representing up to 120,513,483 ($\pm 2,312,391$) inpatient discharges in the United States across 11 years.
- Neither medication nor laboratory information was available in the data source.
- We overcame the inherent imbalance of characteristics between hospitalizations with vs. without hyperkalemia by performing additional analyses on a propensity score matched data set, which made our conclusions more robust.

INTRODUCTION

Hyperkalemia, potassium levels above the upper limit of normal, is rare in the general population, but may be a concern for individuals with renal insufficiency, type II diabetes mellitus (T2DM), and/or congestive heart failure (HF) as a natural consequence of disease or corresponding medication.¹ Many of the medications used to treat these comorbidities may induce hyperkalemia either by altering the cellular shift of potassium or by impairing the kidneys' ability to excrete it.² Although mild hyperkalemia may be asymptomatic, when potassium levels are very high (>6.5 mmol/L), life-threatening cardiac arrhythmias, muscle weakness, and/or paralysis may occur; even mild hyperkalemia can cause permanent damage, if left untreated.^{1,3,4} Because the comorbidity burden and subsequent requirement for chronic medications has amplified in America as the population has become increasingly older, it is imperative to study the trends of hyperkalemia in America over time.^{5,6,7} Hence, the purpose of this paper is to study the trends of hyperkalemia in Americans hospitalized with HF, chronic kidney disease (CKD)/end stage renal disease (ESRD), acute kidney injury (AKI), and/or T2DM from 2004-2014 with respect to prevalence and inpatient mortality.

MATERIALS AND METHODS

This research was approved by the Baylor Scott & White Research Institute's Institutional Review Board via expedited review and was found to be exempt due to being secondary research; informed consent was not required. Neither patients nor the public were involved in the design, conduct, reporting, dissemination plans of this research.

Data

Data Source

1
2
3 The NIS is the largest database developed for the Healthcare Cost and Utilization Project,
4 comprised of approximately 20% of hospitals in the United States, housing approximately 8
5 million discharge records per year, allowing inferences to be made on approximately 97% of
6 U.S. population.⁸ The NIS has a complex sample design. From 1998 – 2011, 100% of discharges
7 were collected from 20% of U.S. hospitals; from 2012 onward, a 20% national patient-level
8 sample has been utilized.^{9, 10} To calculate national estimates, users must account for hospital
9 clusters, stratification, and sample weights (accounting for the sample design change in 2012, if
10 performing a trend analysis).¹¹ The database may be used to evaluate inpatient mortality.¹²
11
12
13
14
15
16
17
18
19
20
21

22 *Key Variables:*
23
24

25 This cross-sectional observational study was designed to examine any hospital discharge
26 in the NIS from 2004-2014 for adults (age ≥ 18 years) with HF, CKD/ESRD, AKI, and/or
27 T2DM. We used methodology described in Healthcare Cost and Utilization Project (HCUP)
28 documentation to search for diagnoses of interest, as documented with ICD-9-CM codes, through
29 the 15th diagnostic position. For example, if the code ‘428.X’ was present in any of the first 15
30 listed diagnoses associated with the hospitalization, we flagged the record as having HF and
31 included it in this analysis. We modified the Elixhauser diabetes comorbidities code sets to select
32 cases specifically with T2DM, and to combine ‘complicated and uncomplicated’ classes.
33
34 Similarly, we identified the primary condition of interest, hyperkalemia, by searching through
35 the 15th diagnostic position for the ICD-9-CM code ‘276.7.’ We were then able to calculate
36 prevalence using the binary indicator variable for hyperkalemia. We also incorporated
37 information from the severity files available from NIS which contain information on Elixhauser
38 comorbidities. The endpoint of inpatient mortality was all available on the yearly NIS core files
39 provided from HCUP.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data cleaning

The data required a minimal amount of cleaning prior to matching and analyses. Due to sparse categories, we combined levels of primary payor so that ‘self-pay’, ‘no charge’, and ‘other’ were combined into 1 group. We did the same for race/ethnicity, combining Asian, Native American, other, and unknown. Finally, we did the same for the All-Patient Refined Diagnosis Related Groups (APR-DRG) severity variable, such that those with no loss of function and those with minor loss of function were combined into 1 group. Data were missing at low rates and were imputed as follows. If weekend admission was missing, we assigned a value of 0 (this occurred nearly 0%). If gender was missing, we designated female as the default – we did so because there were slightly more women in the sample, and gender was missing at a very small rate (0.03%). Median income quartile was missing at the highest rate (2.06%) and we created an imputation rule with a multivariable model using factors that were found to be significantly associated with it (race, gender, T2DM, hospital region, hospital location/teaching status, and hospital bed size).

Propensity Score Matching

We conducted the matched case-control portion of the study using a greedy nearest neighbor matching algorithm such that 1 record with hyperkalemia was matched without replacement to the 1 record without hyperkalemia having the closest propensity score (PS). We set a caliper boundary of 0.25 to achieve reasonable matches (if the closest possible match had a difference in score > 0.25 , the case was unmatched and excluded from analyses). Following the work of potassium-specific analyses and NIS-specific analyses, such as those by Basnet and colleagues, Tanenbaum and colleagues, and Ahmed and colleagues, we created the regression model (using hyperkalemia as the outcome) based on the following independent predictors: age,

1
2
3 gender, race/ethnicity, median zip code income quartile, weekend admission, primary payor,
4 smoking status, HF, CKD/ESRD, T2DM, APRDRG severity, hypertension (HTN), obesity,
5 hospital region, hospital location/teaching status, hospital bed size.^{13,14,15} Because it was our
6 intention from the beginning of this project to conduct subgroup analyses according to primary
7 diagnosis and to draw inferences on trends over time, we conducted the matching within year-
8 specific files by primary diagnosis. Doing so ensured a PS-matched dataset with balanced
9 allocation by year and primary diagnosis. To improve model convergence for the relatively small
10 subgroup of CKD/ESRD primary diagnosis, we did not match on HTN, obesity, smoking,
11 gender, or hospital location; these factors did not differ according to hyperkalemia presence. We
12 excluded records with a primary diagnosis of hyperkalemia prior to matching.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Statistical Analyses**

28
29
30 Due to the complex design of the NIS, as well as its re-structuring in 2012, the
31 calculation of summary statistics for this trend study required additional steps compared to a
32 cross-sectional analysis. We applied specialized discharge weights provided from HCUP
33 ('trendwt' for years 2004-2011 and 'discwt' for years 2012-2014) to calculate the statistics. We
34 used the 'surveymeans' and 'surveyfreq' procedures in SAS to account for clustering by hospital,
35 stratification by 'NIS stratum,' and discharge record weight assignment. Categorical results are
36 presented as percent and standard error. To compare characteristics between groups, we followed
37 the work of Rosenbaum and Rubin, considering an absolute value of the standardized difference
38 > 0.10 to be significantly different.¹⁶ We utilized the 'surveylogistic' procedure to evaluate a
39 trend in prevalence over time, as well as to assess the significance of hyperkalemia presence on
40 trends in inpatient mortality rates over time.
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **RESULTS:**

Unmatched analysis

To achieve our objective regarding prevalence, we required the use of an unmatched data set. There was a total of 24,941,608 discharge records of patients aged ≥ 18 years in the NIS from 2004-2014 with presence of CHF, CKD/ESRD, AKI, or T2DM, which represent a total of 120,513,483 ($\pm 2,312,391$) inpatient discharges in the US. In this cohort we found a total of 1,397,573 records containing hyperkalemia, which represent a total of 6,761,577 ($\pm 149,409$) discharges in the US. This corresponds to an average annual prevalence of 5.61%, which increased over time from 4.94% \pm 0.07% in 2004 to 6.37% \pm 0.04% in 2014, a relative increase of 28.9% ($p < 0.0001$, Figure 1). Partly due to the large sample size, significant differences between groups were observed in every variable examined (Table 1); however, the distributions of age, gender, HF, and hospital characteristics were similar between those who did vs. did not have hyperkalemia. African Americans and Hispanics had a higher risk of hyperkalemia than Caucasians. Hospitalizations including hyperkalemia had higher rates of renal dysfunction (acute and chronic) and major/extreme loss of function (APR-DRG severity).

Inpatient mortality rates were significantly higher for cases with vs. without hyperkalemia (average absolute difference = 4.0%, average relative difference=97.81%, $p < 0.0001$), and the rate decreased non-uniformly between groups over time, decreasing at a faster rate for cases with hyperkalemia (10.91% \pm 0.17% to 6.23% \pm 0.08%) than for cases without hyperkalemia (4.81% \pm 0.05% to 3.8% \pm 0.03%) ($p_{\text{year}} < 0.0001$, $p_{\text{interaction}} < 0.0001$, Figure 2).

Matched Analysis

To achieve our objective regarding inpatient mortality rates while accounting for confounders, we performed PS-matching. After matching, we had a total of 2,606,462 records,

1
2
3 representing 12,517,269 ($\pm 174,562$) hospital discharges. The unweighted records reflect the 1:1
4 matching (i.e., 1,303,231 records in each group), but they represent an odd number of discharges
5 due to records having unequal weights. Patient characteristics were well balanced, with
6 standardized differences all < 0.10 (Table 1). Note that because we excluded cases of
7 hyperkalemia as the primary diagnosis for the matched analyses, the cases with hyperkalemia
8 and their characteristics are not identical to those in the unmatched cohort.
9

10
11
12 Inpatient mortality rates were significantly higher for cases with vs. without
13 hyperkalemia (average absolute difference=1.71%, average relative difference=25.3%, $p <$
14 0.0001), and the rate decreased uniformly between groups over time, decreasing from
15 11.49% $\pm 0.17\%$ to 6.43% $\pm 0.08\%$ for cases with hyperkalemia and from 9.67% $\pm 0.13\%$ to
16 5.05% $\pm 0.07\%$ for cases without hyperkalemia ($p < 0.0001$, Figure 3).
17
18

19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

DISCUSSION

In this study considering adult inpatient hospitalizations with HF, CKD/ESRD, AKI, and/or T2DM, we found a relative increase of 28.9% in hyperkalemia prevalence (from 4.94% in 2004 to 6.37% in 2014). We found that hospitalizations in which hyperkalemia occurred were far more likely to be severe in nature. Accordingly, we found that the presence of hyperkalemia was associated with a higher rate of inpatient mortality. Further, after controlling for primary diagnosis, severity of illness, comorbidities, hospital characteristics, and socio-demographics, we found that the presence of hyperkalemia continued to play a significant role in inpatient mortality risk. We also observed significant reductions in inpatient mortality over time.

Our work reiterates and extends findings from Betts and colleagues, who determined that the prevalence of hyperkalemia among patients with CKD and/or HF increased from 4.95% to 6.35% (a relative increase of 28.2%) using insurance claims records and laboratory test results

1
2
3 from 2010-2014 in the Truven MarketScan claims and encounters database.¹⁷ The nearly 30%
4
5 increase in hyperkalemia prevalence in Betts' study, as well as in our current examination of
6
7 inpatient hospitalizations may be partially explained by the aging population, increasing
8
9 comorbidity burden, and need for chronic/multiple medications.^{3,4} Additionally, our timeframe is
10
11 large enough such that improved abilities and/or standards of documentation may have been
12
13 adopted by hospitals over time.¹⁸ For example, it is possible that the implementation of
14
15 specialized tools within electronic health systems over time may have made the documentation
16
17 of multiple diagnoses easier.¹⁹ Similarly, another possible explanation is that general awareness
18
19 of hyperkalemia may have increased over time and that physicians became more likely to screen
20
21 for it. For example, searching PubMed for the term 'hyperkalemia' yields 206 and 357 papers for
22
23 2004 and 2014, respectively.
24
25
26
27
28

29 Our findings extend those of Singer and colleagues' cross-sectional study which
30
31 determined that hyperkalemia was independently associated with greater risk of inpatient
32
33 admission (80% vs. 39% from patients in the emergency department with moderate
34
35 hyperkalemia vs. normal potassium levels, respectively) and mortality (5.5% vs. 0.8% among
36
37 those with moderate hyperkalemia vs. normal potassium levels, respectively).²⁰ Similarly, Davis
38
39 and colleagues found that having severe hyperkalemia increased the risk of inpatient mortality by
40
41 58.5% compared to having mild hyperkalemia (19.5% vs 12.3%).²¹ Cheunpasitporn and
42
43 colleagues found mild hyperkalemia to carry an associated 22% increased risk of inpatient
44
45 mortality among those with CKD, after adjusting for confounders.²² While we do not know the
46
47 severity of hyperkalemia in our study, our results are similar in that the presence of hyperkalemia
48
49 was associated with an average 25% increase in the risk for mortality in the matched analysis and
50
51 a 98% increase in the unmatched analysis. In general, hyperkalemia's association with increased
52
53
54
55
56
57
58
59
60

1
2
3 risk of mortality may simply be reflective of a more severe overall presentation, or it may
4 contribute to death by complicating an already difficult-to-treat disease state, or even more
5 directly by inducing life-threatening cardiac arrhythmias.^{23,1} Our observation of mortality rates
6 declining over time may be reflective of the large percentage of records with CKD in this study,
7 as it has been shown that CKD mortality rates in Medicare beneficiaries have declined over time
8 but remain significantly higher than the rates observed in patients without CKD.²⁴ Further, the
9 declining rates may be partially attributable to advancements in technology and medical care
10 delivery. For example, increased use of point-of-care potassium testing could have resulted in
11 faster delivery of care.²⁵

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Although we observed a significant increase in its prevalence, as well as a higher mortality rate for those who have it, preventing and treating hyperkalemia is possible. In some cases, particularly patients with CKD at risk for chronic hyperkalemia, a potassium-restricted diet may be beneficial.²⁶ For cases of drug-induced hyperkalemia, interrupting the prescription may be a solution; however, new challenges may arise if the medication was for the management of a chronic condition, which is often true.² Alternatively, diuretics may be used to increase potassium excretion via urine and dialysis may be used to remove excess potassium from blood. In the setting of a hyperkalemic emergency, an intravenous infusion of calcium and insulin may be used to both protect the heart and cause a cellular shift of potassium. Another treatment for hyperkalemia is potassium-binding medication, which expels excess potassium through fecal matter.²⁷ One such drug is sodium polystyrene sulfonate (SPS), which has been used since the late 1950's, but is associated with serious gastrointestinal side effects (and even colonic necrosis in rare cases) and has a relatively low adherence rate.²⁸ Two additional drugs, sodium zirconium cyclosilicate and patiromer, help patients achieve and maintain normal potassium levels.²⁹ These

1
2
3 have advantages over SPS in that they are associated with fewer side effects and they may be
4
5 efficacious regardless of RAASi and/or diet.²⁵ These newer drugs received FDA approval after
6
7 our study timeframe, so they do not explain our observed reduction in mortality rate; however, it
8
9 is of interest to determine whether these rates have further declined since their availability.
10
11

12
13 The study was designed to examine any record with HF, CKD/ESRD, AKI, or T2DM.
14
15 Doing so provided a very large and rich dataset for studying hyperkalemia trends in in-patient
16
17 hospitalizations. Due to the broad inclusion criteria of these analyses, this work did not shed light
18
19 on comparisons within specific types of hospitalizations (i.e., according to primary diagnosis). In
20
21 this paper, we overcame the inherent imbalance of characteristics between hospitalizations with
22
23 vs. without hyperkalemia by performing additional analyses on a PS-matched data set, which
24
25 made our conclusions more robust. Further, we conducted the PS-matching within specific
26
27 primary diagnoses because it is our intention to perform subgroup analyses according to primary
28
29 diagnosis in future work.
30
31
32
33

34
35 Limitations of this study include that the timeframe under evaluation ended in 2014; this
36
37 was due to availability of data and to maintain consistency with ICD-9-CM coding. We
38
39 acknowledge that there may be additional epidemiological changes to the data since then,
40
41 particularly following the introduction of newer therapies for hyperkalemia. Hence, it may be of
42
43 interest to conduct this study using more recent data. Additionally, because the NIS is de-
44
45 identified, it is possible that an individual may be present in the data more than once without
46
47 means to identify such an occurrence; for that reason, the data are interpreted as independent
48
49 hospital discharges, not as patients. Additionally, laboratory results are not available in the NIS.
50
51 As such, the definition of hyperkalemia in this study was based on its ICD code and limits our
52
53 conclusions regarding potential causes of mortality, as the severity of hyperkalemia is unknown.
54
55
56
57
58
59
60

1
2
3 Similarly, medications are not available in the NIS and we are unable to make inferences
4
5 regarding the effects of therapies received. Further, cause of death is not available in this data
6
7 source. Finally, there were instances in which there was only 1 cluster within a stratum, so the
8
9 standard error could not be calculated; however, this happened in less than 1% of the data. While
10
11 this work's data source represents up to 97% of United States hospital discharges, more work is
12
13 needed to understand whether these findings generalize to other countries.
14
15

16 17 **CONCLUSION**

18
19
20 In this large 10-year study of inpatient hospitalizations, hyperkalemia became more
21
22 prevalent and was associated with greater illness severity and inpatient mortality than
23
24 hospitalizations without hyperkalemia. Inpatient mortality rates decreased in this timeframe,
25
26 regardless of hyperkalemia presence; however, the risk of death remained higher when
27
28 hyperkalemia was present.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author Contributions:

KMT – Design, data acquisition, analyses, interpretation, drafting, critical revision, approval, and accountability.

RAB – Interpretation, critical revision, approval, and accountability.

LC – Interpretation, critical revision, approval, and accountability.

PMC – Design, interpretation, critical revision, approval, and accountability.

Data Availability

The National Inpatient Sample data files are available for purchase through the Online HCUP Central Distributor; all HCUP data users must complete the HCUP Data Use Agreement Training Tool, and read and sign the Data Use Agreement for Nationwide Databases.

Conflicts of Interest

The authors have nothing to disclose.

REFERENCES

- ¹ Simon LV, Hashmi MF, Farrell MW. Hyperkalemia. [Updated 2020 Jul 20]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
- ² Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. *Drug Saf.* 2014 Sep;37(9):677-92. doi: 10.1007/s40264-014-0196-1. PMID: 25047526.
- ³ McCullough PA, Beaver TM, Bennett-Guerrero E, Emmett M, Fonarow GC, Goyal A, Herzog CA, Kosiborod M, Palmer BF. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. *Rev Cardiovasc Med.* 2014;15(1):11-23. PubMed PMID: 24762462.
- ⁴ Grodzinsky A, Goyal A, Gosch K, McCullough PA, Fonarow GC, Mebazaa A, Masoudi FA, Spertus JA, Palmer BF, Kosiborod M. Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. *Am J Med.* 2016 Apr 7. pii:S0002-9343(16)30317-5. doi: 10.1016/j.amjmed.2016.03.008. [Epub ahead of print] PubMed PMID: 27060233.
- ⁵ Mather M, Jacobsen LA, Pollard KM. Aging in the United States. Population Bulletin 70, no. 2 (2015). Available at: <https://www.prb.org/wp-content/uploads/2016/01/aging-us-population-bulletin-1.pdf>
- ⁶ Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in Obesity Among Adults in the United States, 2005 to 2014. *JAMA.* 2016 Jun 7;315(21):2284-91. doi: 10.1001/jama.2016.6458. PubMed PMID: 27272580.
- ⁷ McCullough PA, Rangaswami J. Real or Perceived: Hyperkalemia Is a Major Deterrent for Renin-Angiotensin Aldosterone System Inhibition in Heart Failure. *Nephron.* 2017 Dec 5. doi: 10.1159/000485645. [Epub ahead of print] PubMed PMID: 29207385.

⁸ HCUP Database. Healthcare Cost and Utilization Project (HCUP) available at <https://www.hcup-us.ahrq.gov>.

⁹ Khera R, Krumholz HM. With great power comes great responsibility: big data research from the national inpatient sample. *Circ Cardiovasc Qual Outcomes*. 2017 Jul;10(7):e003846. doi: 10.1161/CIRCOUTCOMES.117.003846. PMID: 28705865; PMCID: PMC5728376.

¹⁰ Houchens RL, Elixhauser A, Jiang J. "Nationwide Inpatient Sample redesign final report." Rockville, MD: Agency for Healthcare Research and Quality (2014).

¹¹ HCUP Methods Series. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality; 2016. www.hcup-us.ahrq.gov/reports/methods/methods.jsp. Accessed December 5, 2016.

¹² Hashimoto RE, Brodt ED, Skelly AC, Dettori JR. Administrative database studies: goldmine or goose chase?. *Evid Based Spine Care J*. 2014;5(2):74-6.

¹³ Basnet S, Dhital R, Tharu B, Ghimire S, Poudel DR, Donato A. Influence of abnormal potassium levels on mortality among hospitalized heart failure patients in the US: data from National Inpatient Sample. *J Community Hosp Intern Med Perspect*. 2019 Apr 12;9(2):103-107. doi: 10.1080/20009666.2019.1593778. PMID: 31044040; PMCID: PMC6484484.

¹⁴ Tanenbaum JE, Lubelski D, Rosenbaum BP, Benzel EC, Mroz TE. Propensity-matched Analysis of Outcomes and Hospital Charges for Anterior Versus Posterior Cervical Fusion for Cervical Spondylotic Myelopathy. *Clin Spine Surg*. 2017 Nov;30(9):E1262-E1268. doi: 10.1097/BSD.0000000000000402. PMID: 27352367; PMCID: PMC5191994.

¹⁵ Ahmed MI, Ekundayo OJ, Mujib M, Campbell RC, Sanders PW, Pitt B, Perry GJ, Bakris G, Aban I, Love TE, Aronow WS, Ahmed A. Mild hyperkalemia and outcomes in chronic heart

- failure: a propensity matched study. *Int J Cardiol.* 2010 Oct 29;144(3):383-8. doi: 10.1016/j.ijcard.2009.04.041. Epub 2009 Jun 5. PMID: 19500863; PMCID: PMC2888731.
- ¹⁶ Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. *The American Statistician.* 1985;39:33–38.
- ¹⁷ Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. *Curr Med Res Opin.* 2018;34(6):971-978. doi:10.1080/03007995.2018.1433141
- ¹⁸ Evans RS. Electronic Health Records: Then, Now, and in the Future. *Yearb Med Inform.* 2016;Suppl 1(Suppl 1):S48-S61. Published 2016 May 20. doi:10.15265/IYS-2016-s006
- ¹⁹ Vawdrey DK, Walsh C, Stetson PD. An integrated billing application to streamline clinician workflow. *AMIA Annu Symp Proc.* 2014;2014:1141-1149. Published 2014 Nov 14.
- ²⁰ Singer AJ, Thode HC Jr, Peacock WF. A retrospective study of emergency department potassium disturbances: severity, treatment, and outcomes. *Clin Exp Emerg Med.* 2017 Jun 30;4(2):73-79. doi: 10.15441/ceem.16.194. PMID: 28717776; PMCID: PMC5511959.
- ²¹ Davis J, Israni R, Mu F, Betts KA, Cook EE, Anzalone D, Szerlip H, Doctor T, Yin L, Uwaifo G, Fonseca V, Wu EQ. Management of Hyperkalemic Patients in the Inpatient Setting by Hyperkalemia Severity. *JMCP.* 2019; 25(3-a):S44-45.
- ²² Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Sakhuja A, Mao MA, Erickson SB. Impact of admission serum potassium on mortality in patients with chronic kidney disease and cardiovascular disease. *QJM: An International Journal of Medicine.* 2017;110(17):713–719. Available at: <https://doi.org/10.1093/qjmed/hcx118>
- ²³ Ferreira JP, Claggett BL, Liu J, Desai AS, Pfeffer MA, Anand IS, Van Veldhuisen DJ, Kober L, Cleland JGF, Rouleau JL, Packer M, Zile MR, Shi VC, Lefkowitz MP, Shah SJ, Vardeny O,

1
2
3
4 Zannad F, Solomon SD, McMurray JJV. Serum potassium and outcomes in heart failure with
5 preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. *Eur J Heart Fail*.
6
7 2021 Feb 20. doi: 10.1002/ejhf.2134. Epub ahead of print. PMID: 33609066.
8
9

10
11
12 ²⁴ NIDDK. Kidney Disease Statistics for the United States. 2016. Available at:
13 <https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease>, accessed
14
15 16MAR2021.
16
17

18
19 ²⁵ You JS, Park YS, Chung HS, et al. Evaluating the utility of rapid point-of-care potassium
20 testing for the early identification of hyperkalemia in patients with chronic kidney disease in the
21 emergency department. *Yonsei Med J*. 2014;55(5):1348-1353. doi:10.3349/ymj.2014.55.5.1348
22
23
24

25
26 ²⁶ Cupisti A, Kovesdy CP, D'Alessandro C, Kalantar-Zadeh K. Dietary Approach to Recurrent or
27 Chronic Hyperkalaemia in Patients with Decreased Kidney Function. *Nutrients*. 2018
28 Feb;10(3):261. doi: 10.3390/nu10030261. PMID: 29495340; PMCID: PMC5872679.
29
30
31

32
33 ²⁷ McCullough PA, Costanzo MR, Silver M, Spinowitz B, Zhang J, Lepor NE. Novel Agents for
34 the Prevention and Management of Hyperkalemia. *Rev Cardiovasc Med*. 2015;16(2):140-55.
35
36 PubMed PMID: 26198561.
37
38

39
40 ²⁸ Nguyen T, Ondrik D, Zhufyak O, To W, He S. Hyperkalemia and potential pitfalls of sodium
41 polystyrene sulfonate. *JAAPA*. 2015 Mar;28(3):41-5. doi:
42
43 10.1097/01.JAA.0000458856.92020.1e. PMID: 25710403.
44
45

46
47 ²⁹ Palmer BF. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-
48 Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis. *Mayo Clin Proc*. 2020
49 Feb;95(2):339-354. doi: 10.1016/j.mayocp.2019.05.019. Epub 2019 Oct 23. PMID: 31668450.
50
51
52

Figure Headers

Figure 1. Prevalence of hyperkalemia in inpatient hospitalizations including congestive heart failure, chronic kidney disease (and end stage renal disease), acute kidney injury, and/or type II diabetes mellitus

Figure 2. Annual in-hospital mortality rates (with standard error bars) for the unmatched cohort according to presence of hyperkalemia in hospitalizations including congestive heart failure, chronic kidney disease (and end stage renal disease), acute kidney injury, and/or type II diabetes mellitus

Figure 3. Annual in-hospital mortality rates (with standard error bars) for the propensity score-matched cohort according to presence of hyperkalemia in hospitalizations including congestive heart failure, chronic kidney disease (and end stage renal disease), acute kidney injury, and/or type II diabetes mellitus

Table 1. Patient characteristics of the unmatched and matched cohorts according to hyperkalemia presence

Characteristic	Unmatched Cohort			Matched Cohort		
	Hyperkalemia Yes	Hyperkalemia No	Standardized Difference	Hyperkalemia Yes	Hyperkalemia No	Standardized Difference
Age Group						
18 - 44	9.05 (0.1)	7.76 (0.07)	0.3999	8.64 (0.1)	8.14 (0.09)	0.0179
45 - 54	11.67 (0.09)	11.97 (0.08)	-0.0990	11.43 (0.09)	10.82 (0.09)	0.0192
55 - 64	18.28 (0.08)	18.4 (0.06)	-0.0426	18.09 (0.08)	16.85 (0.08)	0.0322
65 - 74	21.65 (0.06)	22.56 (0.05)	-0.3623	21.72 (0.06)	22.13 (0.06)	-0.0099
75+	39.35 (0.23)	39.32 (0.19)	0.0066	40.12 (0.23)	42.06 (0.22)	-0.0397
Gender (female)	49.34 (0.09)	51.79 (0.07)	-0.8118	49.43 (0.09)	49.95 (0.08)	-0.0103
Race/ethnicity						
White	53.45 (0.59)	58.94 (0.58)	-0.7165	54.23 (0.59)	55.42 (0.57)	-0.0239
Black	18.62 (0.43)	14.48 (0.33)	0.6359	18.29 (0.42)	17.79 (0.39)	0.0128
Hispanic	9.74 (0.32)	7.98 (0.26)	0.3115	9.4 (0.3)	8.99 (0.3)	0.0140
Other	18.19 (0.64)	18.6 (0.62)	-0.0517	18.08 (0.64)	17.8 (0.63)	0.0074
Heart failure	38.6 (0.16)	37.41 (0.12)	0.2958	39.26 (0.16)	39.33 (0.15)	-0.0013
CKD/ESRD	56.84 (0.18)	28.36 (0.12)	6.6531	55.42 (0.18)	54.53 (0.16)	0.0179
Acute kidney injury	49.53 (0.18)	20.12 (0.11)	6.955	51.04 (0.18)	42.31 (0.16)	0.1746
T2DM	47.28 (0.13)	60.07 (0.11)	-3.4897	46.92 (0.14)	46.69 (0.13)	0.0047
Hypertension	61.95 (0.16)	67.85 (0.12)	-1.4971	60.5 (0.16)	60.81 (0.15)	-0.0065
Obesity	11.4 (0.1)	13.92 (0.09)	-0.8082	11.93 (0.1)	11.18 (0.09)	0.0231
Smoker	7.68 (0.08)	9.69 (0.08)	-0.7077	7.58 (0.08)	6.86 (0.07)	0.0272
Primary Diagnosis						
Acute kidney Injury	15.01 (0.08)	2.91 (0.02)	4.1859	15.89 (0.09)	15.9 (0.1)	-0.0003
Heart failure	7.99 (0.05)	8.7 (0.04)	-0.3278	8.49 (0.05)	8.51 (0.05)	-0.0006
CKD/ESRD	0.34 (0.01)	0.1 (0)	0.2619	0.36 (0.01)	0.36 (0.01)	0.0002
Other	73.2 (0.09)	84.99 (0.05)	-3.9621	71.6 (0.09)	71.59 (0.1)	0.0003
T2DM	3.45 (0.03)	3.31 (0.02)	0.0840	3.66 (0.03)	3.65 (0.03)	0.0005
Primary payer						
Medicare	70.96 (0.22)	66.93 (0.2)	0.8573	71.07 (0.21)	72.9 (0.2)	-0.0405
Medicaid	10.44 (0.16)	9.07 (0.13)	0.3396	10.25 (0.15)	9.52 (0.14)	0.0239
Private insurance	13.48 (0.14)	17.96 (0.14)	-1.2035	13.59 (0.14)	12.89 (0.13)	0.0205
Other	5.12 (0.15)	6.03 (0.12)	-0.2395	5.09 (0.13)	4.69 (0.1)	0.0186
Zipcode income quartile						
First quartile	33.22 (0.49)	31.3 (0.44)	0.2751	32.9 (0.49)	32.95 (0.46)	-0.0011
Second quartile	27.41 (0.33)	27.78 (0.32)	-0.0646	27.32 (0.34)	27.21 (0.33)	0.0025
Third quartile	22.4 (0.29)	22.8 (0.27)	-0.0745	22.52 (0.29)	22.39 (0.28)	0.0030
Fourth quartile	16.97 (0.44)	18.11 (0.44)	-0.1720	17.26 (0.45)	17.45 (0.43)	-0.0049
Hospital region						
Northeast	17.72 (0.52)	19.39 (0.51)	-0.2331	18.12 (0.53)	18.13 (0.49)	-0.0004

1							
2							
3	Midwest	23.76 (0.58)	23.7 (0.53)	0.0088	23.17 (0.59)	23.12 (0.56)	0.0013
4	South	40.33 (0.74)	39.84 (0.71)	0.0574	40.54 (0.75)	41.07 (0.73)	-0.0108
5	West	18.18 (0.52)	17.07 (0.48)	0.1552	18.17 (0.52)	17.68 (0.5)	0.0127
6							
7	Hospital setting						
8	Rural	11.29 (0.38)	13.1 (0.37)	-0.2952	11.16 (0.38)	11.15 (0.36)	0.0003
9	Urban nonteaching	41.14 (0.7)	41.02 (0.66)	0.0146	41.56 (0.71)	41.49 (0.68)	0.0015
10	Urban teaching	47.57 (0.71)	45.88 (0.68)	0.2017	47.28 (0.72)	47.36 (0.7)	-0.0017
11							
12	Hospital bed size						
13	Small	12.13 (0.31)	13.31 (0.3)	-0.2116	12.03 (0.32)	11.58 (0.28)	0.0140
14	Medium	25.26 (0.52)	25.23 (0.48)	0.0042	25.32 (0.53)	24.92 (0.49)	0.0093
15	Large	62.61 (0.61)	61.46 (0.58)	0.1475	62.64 (0.62)	63.5 (0.58)	-0.0177
16							
17	Weekend admission	21.83 (0.05)	20.68 (0.04)	0.5302	21.99 (0.05)	21.15 (0.05)	0.0203
18	Function Loss						
19	None/minor	0.83 (0.02)	10.25 (0.06)	-6.2509	0.76 (0.02)	0.62 (0.01)	0.0163
20	Moderate	16.51 (0.12)	37.44 (0.1)	-6.0681	15.39 (0.11)	14.51 (0.08)	0.0244
21	Major	60.75 (0.1)	39.51 (0.09)	6.7972	61.03 (0.1)	62.22 (0.08)	-0.0245
22	Extreme	21.91 (0.13)	12.8 (0.08)	2.4879	22.83 (0.14)	22.65 (0.12)	0.0041
23							

CKD = chronic kidney disease; ESRD = end stage renal disease; T2DM = type II diabetes mellitus




Figure 1.

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2.




Figure 3.

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any pre-specified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	2, 6, 7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Case-control: 7-8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	7-8
Study size	10	Explain how the study size was arrived at	8-9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8 (interaction)
		(c) Explain how missing data were addressed	7
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	7

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	-
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8-9
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9; Table 1
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	-
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	-
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	Table 1
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	9-10; Figures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
Discussion			
Key results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Inpatient Hospitalization and Mortality Rate Trends from 2004 – 2014 in the United States: A Propensity Score-Matched Case-Control Study of Hyperkalemia

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-059324.R1
Article Type:	Original research
Date Submitted by the Author:	12-Apr-2022
Complete List of Authors:	Tecson, Kristen; Baylor Scott & White Research Institute, Baylor Heart and Vascular Institute; Texas A&M University College of Medicine, Health Science Center Baker, Rebecca; Baylor Scott & White Research Institute, Baylor Heart and Vascular Institute Clariday, Laura; Baylor Scott & White Research Institute, Baylor Heart and Vascular Institute McCullough, Peter; Cardiorenal Society of America
Primary Subject Heading:	Epidemiology
Secondary Subject Heading:	Diabetes and endocrinology
Keywords:	Heart failure < CARDIOLOGY, Other metabolic, e.g. iron, porphyria < DIABETES & ENDOCRINOLOGY, EPIDEMIOLOGY, Acute renal failure < NEPHROLOGY, Chronic renal failure < NEPHROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Inpatient Hospitalization and Mortality Rate Trends from 2004 – 2014 in the United**
4
5 **States: A Propensity Score-Matched Case-Control Study of Hyperkalemia**
6
7

8 Kristen M. Tecson, PhD^{1,2,3}; Rebecca A. Baker, MSN, APRN, ACNS-BC^{1,2}; Laura Clariday,
9
10
11 CCRC^{1,2}; Peter A. McCullough, MD, MPH⁴
12
13

- 14 1. Baylor Heart and Vascular Institute, Dallas, TX
 - 15 2. Baylor Scott & White Research Institute, Dallas, TX
 - 16 3. Texas A&M University College of Medicine, Dallas, TX
 - 17 4. Cardiorenal Society of America, Phoenix, AZ
- 18
19
20
21

22 **Correspondence:**

23 Kristen M. Tecson, PhD
24 621 N Hall Street, Suite H-030
25 Dallas, TX 75226
26 Kristen.Tecson@bswhealth.org
27 214.820.5451
28
29
30
31

32 **Word Count:** 3757
33

34
35 **Keywords:** Hyperkalemia, potassium, National Inpatient Sample, hospitalization, mortality,
36
37 heart failure, kidney disease, diabetes mellitus
38
39

40 **Funding:** This work was supported by a grant ('ESR-19-20263') from AstraZeneca to the
41
42 Baylor Scott & White Research Institute.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To study the trends of hyperkalemia in United States inpatient hospitalization records with heart failure (HF), chronic kidney disease (CKD), acute kidney injury (AKI), and/or type II diabetes mellitus (T2DM) from 2004-2014 with respect to prevalence and inpatient mortality

Design: Observational cross-sectional and propensity score-matched case-control study

Setting: The National Inpatient Sample (representing up to 97% of inpatient hospital discharge records in the United States) from 2004-2014

Participants: 120,513,483(\pm 2,312,391) adult inpatient hospitalization records with HF, CKD/ESRD, AKI, and/or T2DM

Exposure: Hyperkalemia, defined as the presence of an ICD-9-CM code of '276.7' in any of the first 15 diagnostic codes

Primary and Secondary Outcome Measures: The outcomes of interest are the annual rates of hyperkalemia prevalence and inpatient mortality.

Results: Among 120,513,483(\pm 2,312,391) adult inpatient hospitalizations with HF, CKD/ESRD, AKI, and/or T2DM, we found a 28.9% relative increase of hyperkalemia prevalence from 4.94% in 2004 to 6.37% in 2014 ($p<0.001$). Hyperkalemia was associated with an average of 4 percentage points higher rate of inpatient mortality (1.71 post-matching, $p<0.0001$). Inpatient mortality rates decreased from 11.49% \pm 0.17% to 6.43% \pm 0.08% and 9.67% \pm 0.13% to 5.05% \pm 0.07% for matched cases with and without hyperkalemia, respectively ($p<0.001$).

1
2
3 **Conclusions:** Hyperkalemia prevalence increased over time and was associated with greater
4 inpatient mortality, even after accounting for presentation characteristics. We detected a
5 decreasing trend in inpatient mortality risk, regardless of hyperkalemia presence.
6
7
8
9

10 **Keywords:** Hyperkalemia, potassium, National Inpatient Sample, hospitalization, mortality,
11 heart failure, kidney disease, diabetes mellitus
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Strengths and Limitations

- This is a large study, representing up to 120,513,483 ($\pm 2,312,391$) inpatient discharges in the United States across 11 years.
- Neither medication nor laboratory information is available in the National Inpatient Sample.
- We did not study hypokalemia separately from normokalemia.
- We overcame the inherent imbalance of characteristics between hospitalizations with vs. without hyperkalemia by performing additional analyses on a propensity score matched data set, which made our conclusions more robust.

INTRODUCTION

Hyperkalemia, potassium levels above the upper limit of normal, is rare in the general population, but may be a concern for individuals with renal insufficiency, type II diabetes mellitus (T2DM), and/or congestive heart failure (HF) as a natural consequence of disease or corresponding medication.¹ Many of the medications used to treat these comorbidities may induce hyperkalemia either by altering the cellular shift of potassium or by impairing the kidneys' ability to excrete it.² Although mild hyperkalemia may be asymptomatic, when potassium levels are very high (>6.5 mmol/L), life-threatening cardiac arrhythmias, muscle weakness, and/or paralysis may occur; even mild hyperkalemia can cause permanent damage, if left untreated.^{1,3,4} Because the comorbidity burden and subsequent requirement for chronic medications has amplified in America as the population has become increasingly older, it is imperative to study the trends of hyperkalemia in America over time.^{5,6,7} Hence, the purpose of this paper is to study the trends of hyperkalemia in Americans hospitalized with HF, chronic kidney disease (CKD)/end stage renal disease (ESRD), acute kidney injury (AKI), and/or T2DM from 2004-2014 with respect to prevalence and inpatient mortality.

MATERIALS AND METHODS

This research was approved by the Baylor Scott & White Research Institute's Institutional Review Board via expedited review and was found to be exempt due to being secondary research; informed consent was not required.

Patient and Public Involvement

No patient or public involvement.

Data

Data Source

The National Inpatient Sample (NIS) is the largest database developed for the Healthcare Cost and Utilization Project, comprised of approximately 20% of hospitals in the United States, housing approximately 8 million discharge records per year, allowing inferences to be made on approximately 97% of U.S. population.⁸ The NIS has a complex sample design. From 1998 – 2011, 100% of discharges were collected from 20% of U.S. hospitals; from 2012 onward, a 20% national patient-level sample has been utilized.^{9, 10} To calculate national estimates, users must account for hospital clusters, stratification, and sample weights (accounting for the sample design change in 2012, if performing a trend analysis).¹¹ The database may be used to evaluate inpatient mortality.¹²

Key Variables:

This cross-sectional observational study was designed to examine any hospital discharge in the NIS from 2004-2014 for adults (age ≥ 18 years) with HF, CKD/ESRD, AKI, and/or T2DM. We used methodology described in Healthcare Cost and Utilization Project (HCUP) documentation to search for diagnoses of interest, as documented with ICD-9-CM codes, through the 15th diagnostic position. For example, if the code '428.X' was present in any of the first 15 listed diagnoses associated with the hospitalization, we flagged the record as having HF and included it in this analysis. We modified the Elixhauser diabetes comorbidities code sets to select cases specifically with T2DM, and to combine 'complicated and uncomplicated' classes. Similarly, we identified the primary condition of interest, hyperkalemia, by searching through the 15th diagnostic position for the ICD-9-CM code '276.7.' We were then able to calculate prevalence using the binary indicator variable for hyperkalemia. We also incorporated information from the severity files available from NIS which contain information on Elixhauser

1
2
3 comorbidities. The endpoint of inpatient mortality was all available on the yearly NIS core files
4 provided from HCUP.
5
6

7 8 *Data cleaning* 9

10
11 The data required a minimal amount of cleaning prior to matching and analyses. Due to
12 sparse categories, we combined levels of primary payor so that ‘self-pay’, ‘no charge’, and
13 ‘other’ were combined into 1 group. We did the same for race/ethnicity, combining Asian,
14 Native American, other, and unknown. Finally, we did the same for the All-Patient Refined
15 Diagnosis Related Groups (APR-DRG) severity variable, such that those with no loss of function
16 and those with minor loss of function were combined into 1 group. Data were missing at low
17 rates and were imputed as follows. If weekend admission was missing, we assigned a value of 0
18 (this occurred nearly 0%). If gender was missing, we designated female as the default – we did
19 so because there were slightly more women in the sample, and gender was missing at a very
20 small rate (0.03%). Median income quartile was missing at the highest rate (2.06%) and we
21 created an imputation rule with a multivariable model using factors that were found to be
22 significantly associated with it (race, gender, T2DM, hospital region, hospital location/teaching
23 status, and hospital bed size).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 42 *Propensity Score Matching* 43 44

45 We conducted the matched case-control portion of the study using a greedy nearest
46 neighbor matching algorithm such that 1 record with hyperkalemia was matched without
47 replacement to the 1 record without hyperkalemia having the closest propensity score (PS). We
48 set a caliper boundary of 0.25 to achieve reasonable matches (if the closest possible match had a
49 difference in score > 0.25 , the case was unmatched and excluded from analyses). Following the
50
51
52
53
54
55
56
57
58
59
60

work of potassium-specific analyses and NIS-specific analyses, such as those by Basnet and colleagues, Tanenbaum and colleagues, and Ahmed and colleagues, we created the regression model (using hyperkalemia as the outcome) based on the following independent predictors: age, gender, race/ethnicity, median zip code income quartile, weekend admission, primary payor, smoking status, HF, CKD/ESRD, T2DM, APRDRG severity, hypertension (HTN), obesity, hospital region, hospital location/teaching status, hospital bed size.^{13,14,15} Because the NIS maintains each year of data in a separate file and our goal was to study trends over time (with future study of primary diagnosis), we conducted the matching according to primary diagnosis within year-specific files prior to combining the data. Doing so ensured a PS-matched dataset with balanced case-control representation for each year and primary diagnosis. To improve model convergence for the relatively small subgroup of CKD/ESRD primary diagnosis, we did not match on HTN, obesity, smoking, gender, or hospital location; these factors did not differ according to hyperkalemia presence. We excluded records with a primary diagnosis of hyperkalemia prior to matching.

Statistical Analyses

Due to the complex design of the NIS, as well as its re-structuring in 2012, the calculation of summary statistics for this trend study required additional steps compared to a cross-sectional analysis. We applied specialized discharge weights provided from HCUP ('trendwt' for years 2004-2011 and 'discwt' for years 2012-2014) to calculate the statistics. We used the 'surveymeans' and 'surveyfreq' procedures in SAS to account for clustering by hospital, stratification by 'NIS stratum,' and discharge record weight assignment. Categorical results are presented as percent and standard error. To compare characteristics between groups, we followed the work of Rosenbaum and Rubin, considering an absolute value of the standardized difference

1
2
3 > 0.10 to be significantly different.¹⁶ We utilized the ‘surveylogistic’ procedure to evaluate a
4 trend in prevalence over time, as well as to assess the significance of hyperkalemia presence on
5 trends in inpatient mortality rates over time.
6
7
8
9

10 RESULTS:

11 Unmatched analysis

12
13 To achieve our objective regarding prevalence, we required the use of an unmatched data
14 set. There was a total of 24,941,608 discharge records of patients aged ≥ 18 years in the NIS
15 from 2004-2014 with presence of CHF, CKD/ESRD, AKI, or T2DM, which represent a total of
16 120,513,483 ($\pm 2,312,391$) inpatient discharges in the US. In this cohort we found a total of
17 1,397,573 records containing hyperkalemia, which represent a total of 6,761,577 ($\pm 149,409$)
18 discharges in the US. This corresponds to an average annual prevalence of 5.61%, which
19 increased over time from 4.94% \pm 0.07% in 2004 to 6.37% \pm 0.04% in 2014, a relative increase
20 of 28.9% ($p < 0.0001$, Figure 1). Partly due to the large sample size, significant differences
21 between groups were observed in every variable examined (Table 1); however, the distributions
22 of age, gender, HF, and hospital characteristics were similar between those who did vs. did not
23 have hyperkalemia. African Americans and Hispanics had a higher risk of hyperkalemia than
24 Caucasians. Hospitalizations including hyperkalemia had higher rates of renal dysfunction (acute
25 and chronic) and major/extreme loss of function (APR-DRG severity).
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Inpatient mortality rates were significantly higher for cases with vs. without
48 hyperkalemia (average absolute difference = 4.0%, average relative difference=97.81%, $p <$
49 0.0001), and the rate decreased non-uniformly between groups over time, decreasing at a faster
50
51
52
53
54
55
56
57
58
59
60

rate for cases with hyperkalemia ($10.91\% \pm 0.17\%$ to $6.23\% \pm 0.08\%$) than for cases without hyperkalemia ($4.81\% \pm 0.05\%$ to $3.8\% \pm 0.03\%$) ($p_{\text{year}} < 0.0001$, $p_{\text{interaction}} < 0.0001$, Figure 2).

Matched Analysis

To achieve our objective regarding inpatient mortality rates while accounting for confounders, we performed PS-matching. After matching, we had a total of 2,606,462 records, representing 12,517,269 ($\pm 174,562$) hospital discharges. The unweighted records reflect the 1:1 matching (i.e., 1,303,231 records in each group), but they represent an odd number of discharges due to records having unequal weights. Patient characteristics were well balanced, with standardized differences all < 0.10 (Table 1). Note that because we excluded cases of hyperkalemia as the primary diagnosis for the matched analyses, the cases with hyperkalemia and their characteristics are not identical to those in the unmatched cohort.

Inpatient mortality rates were significantly higher for cases with vs. without hyperkalemia (average absolute difference= 1.71% , average relative difference= 25.3% , $p < 0.0001$), and the rate decreased uniformly between groups over time, decreasing from $11.49\% \pm 0.17\%$ to $6.43\% \pm 0.08\%$ for cases with hyperkalemia and from $9.67\% \pm 0.13\%$ to $5.05\% \pm 0.07\%$ for cases without hyperkalemia ($p < 0.0001$, Figure 3).

DISCUSSION

In this study considering adult inpatient hospitalizations with HF, CKD/ESRD, AKI, and/or T2DM, we found a relative increase of 28.9% in hyperkalemia prevalence (from 4.94% in 2004 to 6.37% in 2014). We found that hospitalizations in which hyperkalemia occurred were far more likely to be severe in nature. Accordingly, we found that the presence of hyperkalemia was associated with a higher rate of inpatient mortality. Further, after controlling for primary

1
2
3 diagnosis, severity of illness, comorbidities, hospital characteristics, and socio-demographics, we
4 found that the presence of hyperkalemia continued to play a significant role in inpatient mortality
5 risk. We also observed significant reductions in inpatient mortality over time.
6
7
8
9

10
11 Our work reiterates and extends findings from Betts and colleagues, who determined that
12 the prevalence of hyperkalemia among patients with CKD and/or HF increased from 4.95% to
13 6.35% (a relative increase of 28.2%) using insurance claims records and laboratory test results
14 from 2010-2014 in the Truven MarketScan claims and encounters database.¹⁷ The nearly 30%
15 increase in hyperkalemia prevalence in Betts' study, as well as in our current examination of
16 inpatient hospitalizations may be partially explained by the aging population, increasing
17 comorbidity burden, and need for chronic/multiple medications.^{3,4} Additionally, our timeframe is
18 large enough such that improved abilities and/or standards of documentation may have been
19 adopted by hospitals over time.¹⁸ For example, it is possible that the implementation of
20 specialized tools within electronic health systems over time may have made the documentation
21 of multiple diagnoses easier.¹⁹ Similarly, another possible explanation is that general awareness
22 of hyperkalemia may have increased over time and that physicians became more likely to screen
23 for it. For example, searching PubMed for the term 'hyperkalemia' yields 206 and 357 papers for
24 2004 and 2014, respectively.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Our findings extend those of Singer and colleagues' cross-sectional study which
44 determined that hyperkalemia was independently associated with greater risk of inpatient
45 admission (80% vs. 39% from patients in the emergency department with moderate
46 hyperkalemia vs. normal potassium levels, respectively) and mortality (5.5% vs. 0.8% among
47 those with moderate hyperkalemia vs. normal potassium levels, respectively).²⁰ Similarly, Davis
48 and colleagues found that having severe hyperkalemia increased the risk of inpatient mortality by
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 58.5% compared to having mild hyperkalemia (19.5% vs 12.3%).²¹ Cheunpasitporn and
4
5 colleagues found mild hyperkalemia to carry an associated 22% increased risk of inpatient
6
7 mortality among those with CKD, after adjusting for confounders.²² While we do not know the
8
9 severity of hyperkalemia in our study, our results are similar in that the presence of hyperkalemia
10
11 was associated with an average 25% increase in the risk for mortality in the matched analysis and
12
13 a 98% increase in the unmatched analysis. In general, hyperkalemia's association with increased
14
15 risk of mortality may simply be reflective of a more severe overall presentation, or it may
16
17 contribute to death by complicating an already difficult-to-treat disease state, or even more
18
19 directly by inducing life-threatening cardiac arrhythmias.^{23,1} Our observation of mortality rates
20
21 declining over time may be reflective of the large percentage of records with CKD in this study,
22
23 as it has been shown that CKD mortality rates in Medicare beneficiaries have declined over time
24
25 but remain significantly higher than the rates observed in patients without CKD.²⁴ Further, the
26
27 declining rates may be partially attributable to advancements in technology and medical care
28
29 delivery, including medications. For example, increased use of point-of-care potassium testing
30
31 could have resulted in faster delivery of care.²⁵

32
33
34
35
36
37
38 Although we observed a significant increase in its prevalence, as well as a higher
39
40 mortality rate for those who have it, preventing and treating hyperkalemia is possible. In some
41
42 cases, particularly patients with CKD at risk for chronic hyperkalemia, a potassium-restricted
43
44 diet may be beneficial.²⁶ For cases of drug-induced hyperkalemia, interrupting the prescription
45
46 may be a solution; however, new challenges may arise if the medication was for the management
47
48 of a chronic condition, which is often true.² Alternatively, diuretics may be used to increase
49
50 potassium excretion via urine and dialysis may be used to remove excess potassium from blood.
51
52
53
54 In the setting of a hyperkalemic emergency, an intravenous infusion of calcium and insulin may
55
56
57
58
59
60

1
2
3 be used to both protect the heart and cause a cellular shift of potassium. Another treatment for
4 hyperkalemia is potassium-binding medication, which expels excess potassium through fecal
5 matter.²⁷ One such drug is sodium polystyrene sulfonate (SPS), which has been used since the
6
7 late 1950's, but is associated with serious gastrointestinal side effects (and even colonic necrosis
8 in rare cases) and has a relatively low adherence rate.²⁸ Two additional drugs, sodium zirconium
9 cyclosilicate and patiromer, help patients achieve and maintain normal potassium levels.²⁹ These
10 have advantages over SPS in that they are associated with fewer side effects and they may be
11 efficacious regardless of RAASi and/or diet.²⁵ These newer drugs received FDA approval after
12 our study timeframe, so they do not explain our observed reduction in mortality rate; however, it
13 is of interest to determine whether these rates have further declined since their availability. For
14 patients taking medication for chronic diseases, incorporating a pharmacist into a team-based
15 management approach may help protect against hyperkalemia.³⁰

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 The study was designed to examine any record with HF, CKD/ESRD, AKI, or T2DM.
33
34 Doing so provided a very large and rich dataset for studying hyperkalemia trends in in-patient
35 hospitalizations. Due to the broad inclusion criteria of these analyses, this work did not shed light
36 on disease-specific inferences. It is possible that the trends observed in this overall cohort may
37 not hold for each specific disease group. In this paper, we overcame the inherent imbalance of
38 characteristics between hospitalizations with vs. without hyperkalemia by performing additional
39 analyses on a PS-matched data set, which made our conclusions more robust. Further, we
40 conducted the PS-matching within specific primary diagnoses because it is our intention to
41 perform subgroup analyses according to primary diagnosis in future work.

42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3 acknowledge that there may be additional epidemiological changes to the data since then,
4 particularly following the introduction of newer therapies for hyperkalemia. Hence, it may be of
5
6 interest to conduct this study using more recent data. Since our interest was strictly in studying
7
8 the presence or absence of elevated potassium (hyperkalemia), our reference group was
9
10 comprised of both normo- and hypokalemic patients; however, it may be of interest in the future
11
12 to study them separately, as others have shown differential mortality rates.¹³ Additionally,
13
14 because the NIS is de-identified, it is possible that an individual may be present in the data more
15
16 than once without means to identify such an occurrence; for that reason, the data are interpreted
17
18 as independent hospital discharges, not as patients. Additionally, laboratory results are not
19
20 available in the NIS. As such, the definition of hyperkalemia in this study was based on its ICD
21
22 code and limits our conclusions regarding potential causes of mortality, as the severity of
23
24 hyperkalemia is unknown. Hence, as with any study utilizing ICD codes, our study may be
25
26 subject to misclassification bias. Similarly, medications are not available in the NIS and we are
27
28 unable to make inferences regarding the effects of therapies received before and/or after
29
30 hyperkalemia diagnosis. Finally, there were instances in which there was only 1 cluster within a
31
32 stratum, so the standard error could not be calculated; however, this happened in less than 1% of
33
34 the data. While this work's data source represents up to 97% of United States hospital
35
36 discharges, more work is needed to understand whether these findings generalize to other
37
38 countries.
39
40
41
42
43
44
45

46 47 48 **CONCLUSION**

49
50 In this large 10-year study of inpatient hospitalizations, hyperkalemia became more
51
52 prevalent and was associated with greater illness severity and inpatient mortality than
53
54 hospitalizations without hyperkalemia. Inpatient mortality rates decreased in this timeframe,
55
56
57

1
2
3 regardless of hyperkalemia presence; however, the risk of death remained higher when
4
5 hyperkalemia was present.
6
7
8
9
10
11
12
13
14
15
16

17 **Author Contributions:**

18
19
20 KMT – Design, data acquisition, analyses, interpretation, drafting, critical revision, approval, and
21
22 accountability.
23
24

25 RAB – Interpretation, critical revision, approval, and accountability.
26
27

28 LC – Interpretation, critical revision, approval, and accountability.
29
30

31 PMC – Design, interpretation, critical revision, approval, and accountability.
32
33

34 **Data Availability**

35
36
37 The National Inpatient Sample data files are available for purchase through the Online HCUP
38
39 Central Distributor; all HCUP data users must complete the HCUP Data Use Agreement
40
41 Training Tool, and read and sign the Data Use Agreement for Nationwide Databases.
42
43
44

45 **Conflicts of Interest**

46
47
48 The authors have nothing to disclose.
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- ¹ Simon LV, Hashmi MF, Farrell MW. Hyperkalemia. [Updated 2020 Jul 20]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
- ² Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. *Drug Saf.* 2014 Sep;37(9):677-92. doi: 10.1007/s40264-014-0196-1. PMID: 25047526.
- ³ McCullough PA, Beaver TM, Bennett-Guerrero E, Emmett M, Fonarow GC, Goyal A, Herzog CA, Kosiborod M, Palmer BF. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management. *Rev Cardiovasc Med.* 2014;15(1):11-23. PubMed PMID: 24762462.
- ⁴ Grodzinsky A, Goyal A, Gosch K, McCullough PA, Fonarow GC, Mebazaa A, Masoudi FA, Spertus JA, Palmer BF, Kosiborod M. Prevalence and Prognosis of Hyperkalemia in Patients with Acute Myocardial Infarction. *Am J Med.* 2016 Apr 7. pii:S0002-9343(16)30317-5. doi: 10.1016/j.amjmed.2016.03.008. [Epub ahead of print] PubMed PMID: 27060233.
- ⁵ Mather M, Jacobsen LA, Pollard KM. Aging in the United States. Population Bulletin 70, no. 2 (2015). Available at: <https://www.prb.org/wp-content/uploads/2016/01/aging-us-population-bulletin-1.pdf>
- ⁶ Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in Obesity Among Adults in the United States, 2005 to 2014. *JAMA.* 2016 Jun 7;315(21):2284-91. doi: 10.1001/jama.2016.6458. PubMed PMID: 27272580.
- ⁷ McCullough PA, Rangaswami J. Real or Perceived: Hyperkalemia Is a Major Deterrent for Renin-Angiotensin Aldosterone System Inhibition in Heart Failure. *Nephron.* 2017 Dec 5. doi: 10.1159/000485645. [Epub ahead of print] PubMed PMID: 29207385.

⁸ HCUP Database. Healthcare Cost and Utilization Project (HCUP) available at <https://www.hcup-us.ahrq.gov>.

⁹ Khera R, Krumholz HM. With great power comes great responsibility: big data research from the national inpatient sample. *Circ Cardiovasc Qual Outcomes*. 2017 Jul;10(7):e003846. doi: 10.1161/CIRCOUTCOMES.117.003846. PMID: 28705865; PMCID: PMC5728376.

¹⁰ Houchens RL, Elixhauser A, Jiang J. "Nationwide Inpatient Sample redesign final report." Rockville, MD: Agency for Healthcare Research and Quality (2014).

¹¹ HCUP Methods Series. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality; 2016. www.hcup-us.ahrq.gov/reports/methods/methods.jsp. Accessed December 5, 2016.

¹² Hashimoto RE, Brodt ED, Skelly AC, Dettori JR. Administrative database studies: goldmine or goose chase?. *Evid Based Spine Care J*. 2014;5(2):74-6.

¹³ Basnet S, Dhital R, Tharu B, Ghimire S, Poudel DR, Donato A. Influence of abnormal potassium levels on mortality among hospitalized heart failure patients in the US: data from National Inpatient Sample. *J Community Hosp Intern Med Perspect*. 2019 Apr 12;9(2):103-107. doi: 10.1080/20009666.2019.1593778. PMID: 31044040; PMCID: PMC6484484.

¹⁴ Tanenbaum JE, Lubelski D, Rosenbaum BP, Benzel EC, Mroz TE. Propensity-matched Analysis of Outcomes and Hospital Charges for Anterior Versus Posterior Cervical Fusion for Cervical Spondylotic Myelopathy. *Clin Spine Surg*. 2017 Nov;30(9):E1262-E1268. doi: 10.1097/BSD.0000000000000402. PMID: 27352367; PMCID: PMC5191994.

¹⁵ Ahmed MI, Ekundayo OJ, Mujib M, Campbell RC, Sanders PW, Pitt B, Perry GJ, Bakris G, Aban I, Love TE, Aronow WS, Ahmed A. Mild hyperkalemia and outcomes in chronic heart

- 1
2
3
4 failure: a propensity matched study. *Int J Cardiol.* 2010 Oct 29;144(3):383-8. doi:
5
6 10.1016/j.ijcard.2009.04.041. Epub 2009 Jun 5. PMID: 19500863; PMCID: PMC2888731.
7
8
9 ¹⁶ Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling
10 methods that incorporate the propensity score. *The American Statistician.* 1985;39:33–38.
11
12
13 ¹⁷ Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of
14 hyperkalemia in the United States. *Curr Med Res Opin.* 2018;34(6):971-978.
15
16 doi:10.1080/03007995.2018.1433141
17
18
19
20
21 ¹⁸ Evans RS. Electronic Health Records: Then, Now, and in the Future. *Yearb Med Inform.*
22 2016;Suppl 1(Suppl 1):S48-S61. Published 2016 May 20. doi:10.15265/IYS-2016-s006
23
24
25
26 ¹⁹ Vawdrey DK, Walsh C, Stetson PD. An integrated billing application to streamline clinician
27 workflow. *AMIA Annu Symp Proc.* 2014;2014:1141-1149. Published 2014 Nov 14.
28
29
30
31 ²⁰ Singer AJ, Thode HC Jr, Peacock WF. A retrospective study of emergency department
32 potassium disturbances: severity, treatment, and outcomes. *Clin Exp Emerg Med.* 2017 Jun
33 30;4(2):73-79. doi: 10.15441/ceem.16.194. PMID: 28717776; PMCID: PMC5511959.
34
35
36
37 ²¹ Davis J, Israni R, Mu F, Betts KA, Cook EE, Anzalone D, Szerlip H, Doctor T, Yin L, Uwaifo
38 G, Fonseca V, Wu EQ. Management of Hyperkalemic Patients in the Inpatient Setting by
39 Hyperkalemia Severity. *JMCP.* 2019; 25(3-a):S44-45.
40
41
42
43
44 ²² Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Sakhuja A, Mao MA,
45 Erickson SB. Impact of admission serum potassium on mortality in patients with chronic kidney
46 disease and cardiovascular disease. *QJM: An International Journal of Medicine.*
47 2017;110(17):713–719. Available at: <https://doi.org/10.1093/qjmed/hcx118>
48
49
50
51
52
53 ²³ Ferreira JP, Claggett BL, Liu J, Desai AS, Pfeffer MA, Anand IS, Van Veldhuisen DJ, Kober
54 L, Cleland JGF, Rouleau JL, Packer M, Zile MR, Shi VC, Lefkowitz MP, Shah SJ, Vardeny O,
55
56
57
58
59
60

1
2
3
4 Zannad F, Solomon SD, McMurray JJV. Serum potassium and outcomes in heart failure with
5 preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. *Eur J Heart Fail*.
6
7 2021 Feb 20. doi: 10.1002/ejhf.2134. Epub ahead of print. PMID: 33609066.
8
9

10
11
12 ²⁴ NIDDK. Kidney Disease Statistics for the United States. 2016. Available at:
13 <https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease>, accessed
14
15 16MAR2021.
16
17

18
19 ²⁵ You JS, Park YS, Chung HS, et al. Evaluating the utility of rapid point-of-care potassium
20 testing for the early identification of hyperkalemia in patients with chronic kidney disease in the
21 emergency department. *Yonsei Med J*. 2014;55(5):1348-1353. doi:10.3349/ymj.2014.55.5.1348
22
23
24

25
26 ²⁶ Cupisti A, Kovesdy CP, D'Alessandro C, Kalantar-Zadeh K. Dietary Approach to Recurrent or
27 Chronic Hyperkalaemia in Patients with Decreased Kidney Function. *Nutrients*. 2018
28 Feb;10(3):261. doi: 10.3390/nu10030261. PMID: 29495340; PMCID: PMC5872679.
29
30
31

32
33 ²⁷ McCullough PA, Costanzo MR, Silver M, Spinowitz B, Zhang J, Lepor NE. Novel Agents for
34 the Prevention and Management of Hyperkalemia. *Rev Cardiovasc Med*. 2015;16(2):140-55.
35
36 PubMed PMID: 26198561.
37
38

39
40 ²⁸ Nguyen T, Ondrik D, Zhufyak O, To W, He S. Hyperkalemia and potential pitfalls of sodium
41 polystyrene sulfonate. *JAAPA*. 2015 Mar;28(3):41-5. doi:
42
43 10.1097/01.JAA.0000458856.92020.1e. PMID: 25710403.
44
45
46

47
48 ²⁹ Palmer BF. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-
49 Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis. *Mayo Clin Proc*. 2020
50 Feb;95(2):339-354. doi: 10.1016/j.mayocp.2019.05.019. Epub 2019 Oct 23. PMID: 31668450.
51
52
53
54
55
56
57

1
2
3
4 ³⁰ Awdishu L, Singh RF, Saunders I, Yam FK, Hirsch JD, Lorentz S, Atayee RS, Ma JD,
5
6
7 Tsunoda SM, Namba J, Mnatzaganian CL, Painter NA, Watanabe JH, Lee KC, Daniels CD,
8
9 Morello CM. Advancing Pharmacist Collaborative Care within Academic Health Systems.
10
11 *Pharmacy (Basel)*. 2019 Oct 11;7(4):142. doi: 10.3390/pharmacy7040142. PMID: 31614555;
12
13
14 PMCID: PMC6958419.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure Headers

Figure 1. Prevalence of hyperkalemia in inpatient hospitalizations including congestive heart failure, chronic kidney disease (and end stage renal disease), acute kidney injury, and/or type II diabetes mellitus

Figure 2. Annual in-hospital mortality rates (with standard error bars) for the unmatched cohort according to presence of hyperkalemia in hospitalizations including congestive heart failure, chronic kidney disease (and end stage renal disease), acute kidney injury, and/or type II diabetes mellitus

Figure 3. Annual in-hospital mortality rates (with standard error bars) for the propensity score-matched cohort according to presence of hyperkalemia in hospitalizations including congestive heart failure, chronic kidney disease (and end stage renal disease), acute kidney injury, and/or type II diabetes mellitus

Table 1. Patient characteristics of the unmatched and matched cohorts according to hyperkalemia presence

Characteristic	Unmatched Cohort			Matched Cohort		
	Hyperkalemia		Standardized Difference	Hyperkalemia		Standardized Difference
	Yes	No		Yes	No	
Age Group						
18 - 44	9.05 (0.1)	7.76 (0.07)	0.3999	8.64 (0.1)	8.14 (0.09)	0.0179
45 - 54	11.67 (0.09)	11.97 (0.08)	-0.0990	11.43 (0.09)	10.82 (0.09)	0.0192
55 - 64	18.28 (0.08)	18.4 (0.06)	-0.0426	18.09 (0.08)	16.85 (0.08)	0.0322
65 - 74	21.65 (0.06)	22.56 (0.05)	-0.3623	21.72 (0.06)	22.13 (0.06)	-0.0099
75+	39.35 (0.23)	39.32 (0.19)	0.0066	40.12 (0.23)	42.06 (0.22)	-0.0397
Gender (female)	49.34 (0.09)	51.79 (0.07)	-0.8118	49.43 (0.09)	49.95 (0.08)	-0.0103
Race/ethnicity						
White	53.45 (0.59)	58.94 (0.58)	-0.7165	54.23 (0.59)	55.42 (0.57)	-0.0239
Black	18.62 (0.43)	14.48 (0.33)	0.6359	18.29 (0.42)	17.79 (0.39)	0.0128
Hispanic	9.74 (0.32)	7.98 (0.26)	0.3115	9.4 (0.3)	8.99 (0.3)	0.0140
Other	18.19 (0.64)	18.6 (0.62)	-0.0517	18.08 (0.64)	17.8 (0.63)	0.0074
Heart failure	38.6 (0.16)	37.41 (0.12)	0.2958	39.26 (0.16)	39.33 (0.15)	-0.0013
CKD/ESRD	56.84 (0.18)	28.36 (0.12)	6.6531	55.42 (0.18)	54.53 (0.16)	0.0179
Acute kidney injury	49.53 (0.18)	20.12 (0.11)	6.955	51.04 (0.18)	42.31 (0.16)	0.1746
T2DM	47.28 (0.13)	60.07 (0.11)	-3.4897	46.92 (0.14)	46.69 (0.13)	0.0047
Hypertension	61.95 (0.16)	67.85 (0.12)	-1.4971	60.5 (0.16)	60.81 (0.15)	-0.0065
Obesity	11.4 (0.1)	13.92 (0.09)	-0.8082	11.93 (0.1)	11.18 (0.09)	0.0231
Smoker	7.68 (0.08)	9.69 (0.08)	-0.7077	7.58 (0.08)	6.86 (0.07)	0.0272
Primary Diagnosis						
Acute kidney Injury	15.01 (0.08)	2.91 (0.02)	4.1859	15.89 (0.09)	15.9 (0.1)	-0.0003
Heart failure	7.99 (0.05)	8.7 (0.04)	-0.3278	8.49 (0.05)	8.51 (0.05)	-0.0006
CKD/ESRD	0.34 (0.01)	0.1 (0)	0.2619	0.36 (0.01)	0.36 (0.01)	0.0002
Other	73.2 (0.09)	84.99 (0.05)	-3.9621	71.6 (0.09)	71.59 (0.1)	0.0003
T2DM	3.45 (0.03)	3.31 (0.02)	0.0840	3.66 (0.03)	3.65 (0.03)	0.0005
Primary payer						
Medicare	70.96 (0.22)	66.93 (0.2)	0.8573	71.07 (0.21)	72.9 (0.2)	-0.0405
Medicaid	10.44 (0.16)	9.07 (0.13)	0.3396	10.25 (0.15)	9.52 (0.14)	0.0239
Private insurance	13.48 (0.14)	17.96 (0.14)	-1.2035	13.59 (0.14)	12.89 (0.13)	0.0205
Other	5.12 (0.15)	6.03 (0.12)	-0.2395	5.09 (0.13)	4.69 (0.1)	0.0186
Zipcode income quartile						
First quartile	33.22 (0.49)	31.3 (0.44)	0.2751	32.9 (0.49)	32.95 (0.46)	-0.0011

1							
2							
3	Second quartile	27.41 (0.33)	27.78 (0.32)	-0.0646	27.32 (0.34)	27.21 (0.33)	0.0025
4	Third quartile	22.4 (0.29)	22.8 (0.27)	-0.0745	22.52 (0.29)	22.39 (0.28)	0.0030
5	Fourth quartile	16.97 (0.44)	18.11 (0.44)	-0.1720	17.26 (0.45)	17.45 (0.43)	-0.0049
6							
7	Hospital region						
8	Northeast	17.72 (0.52)	19.39 (0.51)	-0.2331	18.12 (0.53)	18.13 (0.49)	-0.0004
9	Midwest	23.76 (0.58)	23.7 (0.53)	0.0088	23.17 (0.59)	23.12 (0.56)	0.0013
10	South	40.33 (0.74)	39.84 (0.71)	0.0574	40.54 (0.75)	41.07 (0.73)	-0.0108
11	West	18.18 (0.52)	17.07 (0.48)	0.1552	18.17 (0.52)	17.68 (0.5)	0.0127
12							
13	Hospital setting						
14	Rural	11.29 (0.38)	13.1 (0.37)	-0.2952	11.16 (0.38)	11.15 (0.36)	0.0003
15	Urban nonteaching	41.14 (0.7)	41.02 (0.66)	0.0146	41.56 (0.71)	41.49 (0.68)	0.0015
16	Urban teaching	47.57 (0.71)	45.88 (0.68)	0.2017	47.28 (0.72)	47.36 (0.7)	-0.0017
17							
18	Hospital bed size						
19	Small	12.13 (0.31)	13.31 (0.3)	-0.2116	12.03 (0.32)	11.58 (0.28)	0.0140
20	Medium	25.26 (0.52)	25.23 (0.48)	0.0042	25.32 (0.53)	24.92 (0.49)	0.0093
21	Large	62.61 (0.61)	61.46 (0.58)	0.1475	62.64 (0.62)	63.5 (0.58)	-0.0177
22							
23	Weekend admission	21.83 (0.05)	20.68 (0.04)	0.5302	21.99 (0.05)	21.15 (0.05)	0.0203
24	Function Loss						
25	None/minor	0.83 (0.02)	10.25 (0.06)	-6.2509	0.76 (0.02)	0.62 (0.01)	0.0163
26	Moderate	16.51 (0.12)	37.44 (0.1)	-6.0681	15.39 (0.11)	14.51 (0.08)	0.0244
27	Major	60.75 (0.1)	39.51 (0.09)	6.7972	61.03 (0.1)	62.22 (0.08)	-0.0245
28	Extreme	21.91 (0.13)	12.8 (0.08)	2.4879	22.83 (0.14)	22.65 (0.12)	0.0041
29							

CKD = chronic kidney disease; ESRD = end stage renal disease; T2DM = type II diabetes mellitus

Results shown as percent (standard error)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

108x60mm (300 x 300 DPI)




Figure 2

108x60mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3

108x60mm (300 x 300 DPI)

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any pre-specified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	2, 6, 7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5-6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Case-control: 7-8
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	7-8
Study size	10	Explain how the study size was arrived at	8-9
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8 (interaction)
		(c) Explain how missing data were addressed	7
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	7

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	-
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8-9
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9; Table 1
		(b) Indicate number of participants with missing data for each variable of interest	7
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	-
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	-
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	Table 1
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	9-10; Figures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	-
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	-
Discussion			
Key results	18	Summarise key results with reference to study objectives	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.